EGFR and non-small cell lung carcinoma: A numerically shorter overall survival (OS) was found with the addition of gefitinib to cisplatin plus pemetrexed (21.4 vs. 22.5 months) in the T790M‐negative subgroup among patients with EGFR‐mutant NSCLC after progression following the first line gefitinib therapy in the IMPRESS study.6